El-Meligie S.Taher A.T.Kamal A.M.Youssef A.Pharmaceutical Organic Chemistry DepartmentFaculty of PharmacyCairo UniversityCairo11561Egypt; Pharmaceutical Organic Chemistry DepartmentFaculty of PharmacyOctober University for Modern Sciences and Arts (MSA)GizaEgypt; Pharmaceutical Organic Chemistry DepartmentFaculty of Pharmacy and Drug ManufacturingMisr University for Science and TechnologyGizaEgypt2020-01-092020-01-0920172235234https://doi.org/10.1016/j.ejmech.2016.09.099PubMed ID 27744186https://t.ly/LXv1gScopusA series of chalcone analogous compounds were designed and synthesized. Replacing/substituting the enone or ethylenic bridge of the parent chalcone with rigid heterocyclic moieties or substituted aromatic amines gave nineteen target compounds. Their cytotoxic activities were screened against both breast and liver cancer cells as well as breast and liver normal cells. Target compounds were also evaluated for their inhibition activity of tubulin beta polymerization. Target compound 2e, 3a, 3b, 3c, 4a-4d, 5a, 5b and 6 showed broad spectrum excellent anticancer activity against both MCF-7 and HepG2. Compound 4a showed the most TUBb inhibition activity. � 2016 Elsevier Masson SASEnglishCancer cell linesChalcone derivativesCytotoxic activityNormal cell linesReplacing enone bridgeTubulin beta polymerization inhibitors3 (4 bromophenyl) 3 [(3 chloro 4 fluorophenyl)amino] 2 hydroxy 1 (3 methoxyphenyl)propan 1 one4 (4 bromophenyl) 6 (3 methoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 bromophenyl) 6 (3,4,5 trimethoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 bromophenyl) 6 (4 methoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 chlorophenyl) 6 (3 methoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 chlorophenyl) 6 (3,4,5 trimethoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 flurophenyl) 6 (3,4,5 trimethoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione4 (4 mehoxyphenyl) 6 (3,4,5 trimethoxyphenyl) 3,4 dihydropyrimidine 2(1h) thione45 (4 chlorophenyl) 3 (3 methoxyphenyl) 4,5 dihydro 1h pyrazol 4 ol5 (4 bromophenyl) 3 (3 methoxyphenyl) 1 phenyl 4,5 dihydro 1h pyrazol 4 ol5 (4 bromophenyl) 3 (3 methoxyphenyl) 4,5 dihydro 1h pyrazol 4 ol5 (4 chlorophenyl) 3 (3 methoxyphenyl) 1 phenyl 4,5 dihydro 1h pyrazol 4 ol5 (4 flurophenyl) 3 (4 methoxyphenyl) 1 phenyl 4,5 dihydro 1h pyrazol 4 ol5 (4 methoxyphenyl) 3 (4 methoxyphenyl) 1 phenyl 4,5 dihydro 1h pyrazol 4 olantimitotic agentbeta tubulinchalcone derivativecolchicinecytotoxic agentprotein inhibitorunclassified drug[3 (4 bromophenyl)oxiran 2 yl](3 methoxyphenyl)methanone[3 (4 bromophenyl)thiiran 2 yl](3 methoxyphenyl)methanone[3 (4 chlorophenyl)oxiran 2 yl](3 methoxyphenyl)methanone[3 (4 chlorophenyl)thiiran 2 yl](3 methoxyphenyl)methanone[3 (4 flurophenyl)oxiran 2 yl](4 methoxyphenyl)methanoneantineoplastic agentchalconetubulintubulin modulatorantiproliferative activityArticlecancer inhibitioncomparative studyconcentration responsecontrolled studycytotoxicitydrug cytotoxicitydrug designdrug potencydrug synthesisHepG2 cell linehumanhuman cellMCF 7 cell linemicrotubule assemblyprotein polymerizationbreastcell proliferationchemistrycytologydrug effectsHep-G2 cell lineliverMCF-7 cell linesynthesisAntineoplastic AgentsBreastCell ProliferationChalconeChemistry Techniques, SyntheticDrug DesignHep G2 CellsHumansLiverMCF-7 CellsTubulinTubulin ModulatorsArticlehttps://doi.org/10.1016/j.ejmech.2016.09.099PubMed ID 27744186